Candel Therapeutics, Inc. (CADL)

NASDAQ: CADL · IEX Real-Time Price · USD
6.25 -0.20 (-3.10%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap179.31M
Revenue (ttm)n/a
Net Income (ttm)-48.20M
Shares Out28.69M
EPS (ttm)-3.30
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,656
Open6.45
Previous Close6.45
Day's Range6.00 - 6.85
52-Week Range5.51 - 14.78
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CADL

Candel Therapeutics is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. We have established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs. Our most adv...

IndustryBiotechnology
IPO DateJul 27, 2021
CEOPaul Peter Tak M.D., Ph.D. FMedSci
Employees41
Stock ExchangeNASDAQ
Ticker SymbolCADL
Full Company Profile

Financial Performance

Financial Statements

News

Candel Therapeutics to Present at Two Upcoming Investor Conferences

NEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announ...

1 week ago - GlobeNewsWire

Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Vir...

LOS ANGELES and NEEDHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Bionaut Labs, a company focused on revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut™ precision m...

1 month ago - GlobeNewsWire

Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for ...

NEEDHAM, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announ...

1 month ago - GlobeNewsWire

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in...

NEEDHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announ...

2 months ago - GlobeNewsWire

Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral i...

2 months ago - GlobeNewsWire

Candel Therapeutics to Participate in Three Upcoming Investor Conferences

NEEDHAM, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announ...

2 months ago - GlobeNewsWire

Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies

NEEDHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announ...

2 months ago - GlobeNewsWire

Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clin...

NEEDHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announ...

2 months ago - GlobeNewsWire

Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer

NEEDHAM, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announ...

2 months ago - GlobeNewsWire

Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

NEEDHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announ...

3 months ago - GlobeNewsWire

Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherap...

4 months ago - GlobeNewsWire

Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters' Option

NEEDHAM, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced ...

4 months ago - GlobeNewsWire

Candel Therapeutics Announces Pricing of Initial Public Offering

NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced ...

5 months ago - GlobeNewsWire